Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
New facility ‘Amber Wing’ adds 55 beds and strengthens surgical, cardiac, robotic and preventive care infrastructure for women in Mumbai
The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
Global specialty pipeline accelerates growth
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
Subscribe To Our Newsletter & Stay Updated